

# Drugs Off-Patent Reports

ISSN 0793694X

Electronic  Reports on Disk

Reports on  the Web

e- Reports

2000

Drugs Under \$100 million US Dollars

## Year of Expiration - 1998

<b>Drug ON-OFF Patent</b>	<b>Generic Name</b>	<b>Patent Holder Marketer</b>	<b>Patent Expiry</b>	<b>Exclusivity Expiry</b>	<b>Patent &amp; Exclusivity</b>	<b>Earliest Generic</b>	<b>1998 1999<sup>1</sup></b>
Trade	Generic	NAME	Patent #	DATE	CODES	DATE	USD\$ (Mil)
Femstat	Butoconazole Nitrate.	Roche/Syntex	3/7/95 7/28/95	3/7/95 3/7/97		Expired	Class 1 Class 2
Zonalon	Doxepin HCl	Genderm	7/26/00 12/9/01	4/1/97	NDF	Expired	Class 1 Class 3
Cesamet	Nabilone	Lilly	5/2/95 2/17/96	5/2/97 5/2/97	-	Expired	Class 1 Class 3
Producil	-	Merck Co.	5/17/94 8/13/94	5/17/97 5/17/97	-	Expired	Class 1 Class 3
Opcon-A	Naphoxoline HCl	Bausch & Lomb	6/8/97 NA	- 6/8/97	NC	Expired	Class 1 Class 4
Minizide	Polythiazide	Pfizer	12/19/95 7/8/97	- 7/8/97	-	Expired	Class 1 Class 4
Adagen	PegademaseBovine	Enzon	12/18/96 7/28/97	- 7/28/97	ODE	Expired	Class 1 Class 3
Hexalen	Altretamine	US Bioscience	12/26/97 NA	NA 12/26/97	NCE ODE	Expired	Class 2 Class 2
Capozide	Captopril Hydrochlorothiazide	Bristol Myers Squibb	8/12/97 12/27/97	- 12/27/97	-	Expired	Class 4 Class 6

### USD \$

Class 1 -<10m ; Class 2 -<25m ; Class 3 -<50m ; Class 4 -<75m ; Class 5 -<100m Class 6 ->100m

## Year of Expiration - 1998

Drug ON-OFF Patent	Generic Name	Patent Holder Marketer	Patent Expiry	Exclusivity Expiry	Patent & Exclusivity	Earliest Generic	1998 1999 <sup>1</sup>
Trade	Generic	NAME	Patent #	DATE	CODES	DATE	USD\$ (Mil)
Tonolate	Dihydroxy- alpha-amino methylbenzyl	Sterling	2/6/96 4/1/89	2/6/98 <b>2/6/98</b>		<b>Expired</b>	Class 1 Class 2
Leustatin	Cladribane	JNJ/ Ortho	2/26/98 NA	- 2/26/98	NCE	<b>Expired</b>	Class 2 Class 4
Equestrolin	NA	Merck & Co.	3/21/95 5/9/95	3/21/98 3/21/98		<b>Expired</b>	Class 1 Class 4
Synanthic	Antiparasitic Benzene	Roche/ Syntex	3/21/95 12/29/92	3/21/98 3/21/98	-	<b>Expired</b>	Class 1 Class 3
Chibroxin	Norfloxacin	Merck & Co.	3/27/98 2/16/98	- 3/27/98	-	<b>Expired</b>	Class 1 Class 3
Ceredase	Alglucerase Injection	Genzyme	4/5/98 NA	- 4/5/98	NCE ODE	<b>Expired</b>	Class 2 Class 4
Cerebyx	Fosphenytoin Sodium	WLA / P Davis	4/7/98 NA	- 4/7/98	NCE	<b>Expired</b>	Class 1 Class 3
Cefpiramide Sodium	Cephalosporin Heterocycle	Sumitomo Chemical	5/29/96 9/8/95	5/29/98 5/28/98	-	<b>Expired</b>	Class 1 Class 2
Pilopine HS	NA	Alcon	6/2/98 1/25/98	- 6/2/98	-	<b>Expired</b>	Class 2 Class 2
Cibacalcin	Calcitonin	Ciba- Geigy	6/30/98 6/9/89	- 6/30/98	-	<b>Expired</b>	Class 1 Class 3
Orlaam	Levomethadyl Actate HCl	Roxane	7/9/98 NA	- 7/9/98	NCE	<b>Expired</b>	Class 1 Class 4
Inocor	Amrinone Lactate	Sanofi Winthrop	7/31/98 4-072-746		U7	<b>Expired</b>	Class 2 11
Normodyne Trandate	Labetalol	Schering A7H	8/2/98 4-012-444	-	-	<b>Expired</b>	Class 4 <b>60 + 41</b>
Tonocard	Tocainide HCl	Astra - Merck	12/2/97 7/28/91	9/9/98 9/9/98	-	<b>Expired</b>	Class 1 Class 3
Flumadine	Rimantadine	Forest Labs	9/17/98 NA	- 9/17/98	NCE	<b>Expired</b>	Class 2 Class 4
Nipent	Pentostatin	Parke- Davis	10/11/98 NA	10/11/98	ODE	<b>Expired</b>	Class 1 Class 3
Rocaltrol	Calcitriol	Roche/ Syntex	9/30/97 10/13/98	- 10/13/98		<b>Expired</b>	Class 3 Class 5
DIDRONEL	Etidronate Disodium	P&G	3/3/98 4-254-114	-	-	<b>Expired</b>	Class 2 17
CERVIDIL	Dinoprostone	Forest Labs	12/14/10 5-269-321	3/30/98-	- NDF	<b>Expired</b>	Class 2 29
Transderm SCOP	Scopolamine	Novartis	4/14/98 4-436-741	-	-	<b>Expired</b>	Class 2 21
Tagamet HB	Cimetidine	SKB	- -	6/19/98	- NS	<b>Expired</b>	Class 3 44
Caverject	Alprostadil	Pharmaci a	3/16/97 4-127-188	7/6/98	- NP	<b>Expired</b>	Class 3 34

## Year of Expiration – 1998

Drug ON-OFF Patent	Generic Name	Patent Holder Marketer	Patent Expiry	Exclusivity Expiry	Patent & Exclusivity	Earliest Generic	1998 1999 <sup>1</sup>
Trade	Generic	NAME	Patent #	DATE	CODES	DATE	USD\$ (Mil)
Flumadine	Rimantadine	Forrest	- -	9/17/98	- NCE	Expired	Class 4 60
Metro Cream	Metronidazole		// 4--		- NCE	Expired	Class 2 15
ORUDIS KT	Ketoprofen	AHP	- 20-429	1-/06/98	- NS	Expired	Class 1 9.5
FEMSTAT 3	Butoconazole nitrate	P&G	3/7/97 4-078-071	12/21/98	- NP	Expired	Class 2 12
Dermadex	Torseamide	B Mann	8/11/06 RE-34-672	8/23/98	- NCE	Expired	Class 4 57

### USD \$

Class 1 -<10m ; Class 2 -<25m ; Class 3 -<50m ; Class 4 -<75m ; Class 5 -<100m Class 6 ->100m

## Year of Expiration - 1999

Drug ON-OFF Patent	Generic Name	Patent Holder Marketer	Patent Expiry	Exclusivity Expiry	Patent & Exclusivity	Earliest Generic	1998 1999 <sup>1</sup>
Trade	Generic	NAME	Patent #	DATE	CODES	DATE	USD\$ (Mil)
Didronel	Etidronate Disodium	Procter & Gamble	3/3/98 1/2/98	- 1/2/99	-	//99	Class 3 Class 4
Maxair	Pirbuterol Acetate	3M Phar- maceuticals	11/20/96 1/3/99	- 1/3/99	-	//99	Class 3 Class 4
Tussionex Pennatuss Corsy	Chlorphe- niramine Polistirex	Rhone - Poulenc Rorer	9/9/97 1/8/99	- 1/8/99	-	//99	Class 3 Class 5
Kerlone	Betaxolol	Searle	1/19/99 10/20/96	- 1/19/99	-	//99	Class 2 Class 4
Rhinocort	Budesonide	Astra Zen	2/14/ 99 -	<b>2/14/99</b>	NCE	<b>2/14/99</b>	Class 5 80
Alfenta Inj.	Alfentanil	JNJ/ Jansen	<b>5/5/99</b> <b>4-167-574</b>			//99	Class 1 5
Nizoral	Ketoconazole	JNJ / Jansen	6/15/99 1/31/97	- 6/15/99	I-30	//99	Class 5 Class 6
Acesulfame Potassium	Acetosul- pham, etc.,	Hoechst- Roussel	6/12/96 6/22/97	6/12/98 6/22/99	-	//99	Class 1 Class 3
Tornalate	Bitolterol mesylate	Dura Pharm.	6/22/99 4/1/89	- 6/22/99	-	//99	Class 1 Class 3
Virazole	Ribavirin	ICN Pharm.	7/8/97 6/1/91	7/8/99 7/8/99	-	//99	Class 3 Class 5
Betoptic S	Betaxolal HCl	Alcon	7/24/99 4-252-984	-	-	<b>4/24/99</b>	Class 3 55
Betoptic	Betaxolal HCl	Alcon	7/24/99 4-252-984	-	-	<b>4/24/99</b>	Class 2 22
Tegison	Etretinate	Roche Syntex	7/29/97 3/22/94	7/29/99 7/29/99	-	//99	Class 2 Class 5
Alkeran	Melphalan	Burroughs Wellcome	3/5/08 11/18/08	- 11/18/99	ODE	//99	Class 1 Class 3
Normo- dyne	Labetalol	Schering - Key	5/4/99 11/28/99	- 11/28/99	-	//99	Class 4 Class 6
Luvox	Fluvoxamine Maleate	U.S. Phillips	4/18/95 3/19/96	- 12/5/99	NCE	//99	Class 1 Class 4
Carnitor	Levocarnitine	Sigma Tau	- 19-948	12/16/99	I-86 ODE	<b>12/16/99</b>	Class 2 33
Osmovist	Iotrolan	Schering AG	12/16/97 6/14/97	12/16/99 12/16/99	-	//99	Class 1 Class 3
Marinol	Dronabinol	Roxane BI	12/22/99 NA	- 12/22/99	I-85 ODE	//99	Class 2 Class 0
Ceradon	Cephalosporin Dihydrochloride	Takeda	12/23/97 8/29/97	12/23/99 12/23/99	-	//99	Class 1 Class 3
Navelbine	Vinorelbine Tartrate	Burroughs Wellcome	12/23/99 NA	- 12/23/99	NCE	//99	Class 1 Class 4
Omnipaque	Iohexal	Sanofi Winthrop	2/10/98 6/10/97	12/26/99 12/26/99	I-97	//99	Class 1 Class 3
Mefoxin	Cefoxitin Sodium Inj.	Merck & Co.	8/1/99 NA	--	-	<b>8/1/99</b>	Class 2 27

## Year of Expiration – 1999

Drug ON-OFF Patent	Generic Name	Patent Holder Marketer	Patent Expiry	Exclusivity Expiry	Patent & Exclusivity	Earliest Generic	1998 1999 <sup>1</sup>
Trade	Generic	NAME	Patent #	DATE	CODES	DATE	USD\$ (Mil)
NAPRILAN	Naproxin Na	AHP	16/10/14 5-637-320	1/5/99	- NDF	//99	Class 5 80
Procanbid	Procain- amide HCl	WL	- -	1/31/99	- NP	1/31/99	Class 2 13
CO-VERA HS	Verapamil HCl	Monsanto Searle	6/27/11 5-252-338	2/26/99	- NP	2/26/99	Class 5 78
ACTIGALL	Ersodiol	Bil Therap	- 19-594	3/29/99	- I-147	3/29/99	Class 4 62
Nasacort AQ	Triamcinolon e Acetonide	RPR	- -	5/20/99	- NDF	5/20/99	Class 4 52
Fortaz	Glaxo - Wellcome	Ceftazidime	6/24/99 4-258-041			6/24/99	Class 5 78
Nicoderm CQ	Nicotine	SKB	- -	8/2/99	- NP	8/02/99	Class 4 74
Norcuron	Vecuronium Bromide	Akzo Org	8/20/99 4-297-351	-	-	8/20/99	Class 2 17
Lac-Hydrin	Ammonium Lactate	Westwood		8/29/99	- NDF	8/29/99	Class 4 65
NIX	Permethrin	WL	--	11/1/99	- 170	11/1/99	Class 2 24
Vanceril DS	Beclomethaso ne Dipropionate	S Plough	12/21/99 4-364-923	- -		12/21/99	Class 4 66
Vancenase	Beclomethaso ne Dipropionate	S Plough	12/21/99 4-364-923	- -		12/21/99	Class 3 52
Beclovent	Beclomethaso ne Dipropionate	Glaxo - Wel	12/21/99 4-364-924	- -		12/21/99	Class 2 42
Marinol	Dronabinol	Roxane	- -	12/22/99 -	- ODE	12/22/99	Class 2 23
Acular	Ketorolac Tromethamine	Allergan	5/5/09 5-110-493	12/31/99 -	U-55 I-176	12/31/99	Class 2 44

### USD \$

Class 1 -<10m ; Class 2 -<25m ; Class 3 -<50m ; Class 4 -<75m ; Class 5 -<100m Class 6 ->100m

## Year of Expiration - 2000 Under \$100 million USD

Drug ON-OFF Patent	Generic Name	Patent Holder Marketer	Patent Expiry	Exclusivity Expiry	Patent & Exclusivity	Earliest Generic	1998 1999 <sup>1</sup>
Trade	Generic	NAME	Patent #	DATE	CODES	DATE	USD\$ (Mil)
Sular	Nisoldipine	Astra Zeneca	06/08/08 4-892-741	02/02/00 -	- NCE	02/02/00	Class 3 44
Ocupress	Carteolol	Otsuka	01/02/00 4-309-432	- -	- -	01/02/00	Class 2 18
Retin-A- Micro	Tretinoin	Johnson & Johnson	10/04/05 4-690-825	02/07/00 -	- NP	02/07/00	Class 3 37
Leustatin	Cladribane	Johnson & Johnson	- P	02/26/00	- NCE,ODE	02/26/00	Class 2 13
Condylox	Podofilox	Watson	06/14/04 4-680-399	03/13/00	- NDF	03/13/00	Class 2 15
Zebeta	Bisoprolol fumarate	AHP/Ledeele	03/24/00 4-258-062	07/31/97	U-63 NCE	03/24/00	Class 1 9
Hismanal	Astemizole	Johnson & Johnson	04/03/00 4-219-559	-	- -	04/03/00	Class 3 31
Novantrone	Mitoxantrone	AHP/ACY	07/14/00 4-278-689	- -	- -	07/14/00	Class 3 50
Loprox	Ciclopirox	Hoechst- Marion Roussel	- P	07/21/00	- NDF	07/21/00	Class 2 12
Niaspan	Niacin	Cos Pharmaceuticals	- P	07/28/00	- NDF	07/28/00	Class 2 17
Cytotec	Misoprostol	Monsanto/ Searle	07/29/00 4-301-146	-	- -	07/29/00	Class 4 72
Oxistat	Oxiconazole Nitrate	Glaxo- Wellcome	- P	08/18/00 -	- I-200	08/18/00	Class 2 15
Pepcid AC	Famotidine	Merck & Co.	10/15/00 4-283-408	04/28/98	- NS	10/15/00	Class 5 105
Flagyl ER	Metronidazole	Monsanto/ Searle	- P	11/26/00	- NDF	11/26/00	Class 2 18
Noroxin	Norfloxacin	Merck & Co.	02/16/00 4-146-719	10/24/97	- I-113	02/16/00	Class 3 34
Azelex	Azelaic Acid	Allergan	05/31/00 4-386-104	09/13/00 -	U-124 NCE	09/13/00	Class 1 17
Univasc	Moexipril HCL	Schwarz	10/03/00 4-344-949	04/19/00	- NCE	10/03/00	Class 2 25
Trasylol	Aprotinin Bovine	Bayer	- P	08/28/01	- NCE,ODE, I-233	12/29/00	Class 3 47

Class 1 -<10m ; Class 2 -<25m ; Class 3 -<50m ; Class 4 -<75m ; Class 5 -<100m USD \$

## Year of Expiration – 2001

### Under \$100 million USD

<b>Drug ON-OFF Patent</b>	<b>Generic Name</b>	<b>Patent Holder Marketer</b>	<b>Patent Expiry</b>	<b>Exclusivity Expiry</b>	<b>Patent &amp; Exclusivity</b>	<b>Earliest Generic</b>	<b>1998 1999<sup>1</sup></b>
Trade	Generic	NAME	Patent #	DATE	CODES	DATE	USD\$ (Mil)
Primacor	Milrinone	Sanofi Winthrop	02/02/01 4-313-951	-	- -	02/02/01	Class 5 100+
Mesnex	Mesna	Asta - Werke	03/06/01 4-220-660	-	U-21 -	03/06/01	Class 3 35
Estratab	Estrogens, esterified	Solvay	- P	03/10/01	- I-214	03/10/01	Class 3 24
Differin	Adapalene	Galderma	04/10/01 4-717-720	05/31/01	U-134 NCE	05/31/01	Class 4 75
Stadol	Butorphanol tartrate	Bristol-Myers Squibb	08/07/01 /A4-464-378	-	U-60 -	08/07/01	Class 2 18
Alphagan	Brimonidine tartrate	Allergan	- P	09/06/01	- NCE	09/06/01	Class 5 92
Proamatine	Midazolam	Roberts Pharmaceutical	- P	09/06/01	- NCE	09/06/01	Class 2 12
Eulexin	Flutamide	Schering	09/18/01 4-472-382	06/21/99	U-24 I-168	09/18/01	Class 4 73
Nilandron	Nilutamide	Hoeschst-Marion Roussel	- P	09/19/01	- NCE	09/19/01	Class 2 12
Roxicodone	Oxycodone hydrochloride	Roxane Laboratories	- P	10/26/01	- NS	10/26/01	Class 2 12
Terazol	Terconazole	Johnson & Johnson	11/09/01 4-358-449	-	- -	11/09/01	Class 5 100+
Rocaltrol	Calcitriol	Roche	- P	11/20/01	- NDF	11/20/01	Class 3 39
Zanaflex	Tizanidine HCl	Elan	- P	11/27/01	- NCE	11/27/01	Class 3 28
Chymo-diactin	Chymopapain	Knoll	05/13/01 4-439-423	-	- -	05/13/01	Class 1 2
Tri-Norinyl	Ethinyl Estradiol	Roche Syntex	08/10/01 4-390-531	-	- -	08/10/01	Class 3 36
Elocon	Mometasone Furoate	Schering	09/18/01 4-472-393	- P	- -	09/18/01	Class 4 85
Vaseretic	Enalapril Maleate	Merck & Co.	09/18/01 4-472-380	07/12/98	- NS	09/18/01	Class 4 73
Oxsoralen-Ultra	Methoxsalen	ICN Pharm.	12/20/01 4-454-152	-	- -	12/21/01	Class 1 11

#### USD \$

Class 1-<10m ; Class 2-<25m ; Class 3-<50m ; Class 4-<75m ; Class 5-<100m Class 6->100m USD \$

## Year of Expiration - 2002

### Under \$100 million USD

<b>Drug ON-OFF Patent</b>	<b>Generic Name</b>	<b>Patent Holder Marketer</b>	<b>Patent Expiry</b>	<b>Exclusivity Expiry</b>	<b>Patent &amp; Exclusivity</b>	<b>Earliest Generic</b>	<b>1998 1999<sup>1</sup></b>
Trade	Generic	NAME	Patent #	DATE	CODES	DATE	USD\$ (Mil)
Gastrocrom	Cromolyn Sodium	Rhone Poulenc Rorer	05/07/02 4-515-805	-	- -	05/07/02	Class 1 3
Photoplex	Avobenzone	Allergan	06/07/02 4-387-089	-	- -	06/07/02	NA
Cardiogen-82	Rubidium Chloride	Bristol - Myers Squibb	08/23/02 4-400-358	-	- -	08/23/02	NA
Nimotop	Nimodipine	Bayer AG	09/27/02 4-406-906	-	U-22 -	09/27/02	Class 2 23
Proleukin	Aldesleukin	Chiron	10/18/02 4-518-584	-	- -	10/18/02	Class 3 50
Sandostatin	Octreotide Acetate	Novartis	10/21/02 4-395-403	05/03/97	- I-106	10/21/02	Class 5 85
Cefotan	Cefotetan disodium	Stuart	11/21/99 4-263-432	-	- -	01/12/02	Class 4 53
Coreg	Carvedilol	Smith Kline Beecham	03/05/02 4-503-067	09/14/00	U-3 NCE	03/05/02	Class 5 100+
Agrylin	Anagrelide HCl	Roberts	- -	03/14/02	- NCE,ODE	03/14/02	Class 2 17
Tazorac	Tazarotene	Allergan	02/18/09 5-089-509	06/13/02	U-193 NCE	06/13/02	Class 2 17
Dostinex	Cabergoline	Pharmacia & Upjohn	07/02/02 4-526-892	12/23/01	- NCE	07/02/02	Class 2 22
Navelbine	Vinorelbine tartrate	Glaxo-Wellcome	07/08/02 4-307-100	12/23/99	- NCE	07/08/02	Class 4 63
Duract	Bromfenac sodium	AHP/Wyeth Ayerst	- -	07/15/02	- NCE	07/15/02	Class 3 35
Nolvadex	Tamoxifen citrate	Astra Zeneca	08/20/02 4-536-516	-	- -	08/20/02	Class 5 85
Anzemet	Dolasetron nesylate monohydrate	Hoechst Marrion Roussel	- -	09/11/02	- NCE	09/11/02	Class 3 42
Axiz AR	Nizatidine	Eli Lilly	10/02/02 4-375-547	05/09/99	- NS	10/02/02	Class 2 22
Cytosan	Cyclophosphamide	Bristol-Myers Squibb	11/12/02 4-537-883	-	- -	11/12/02	Class 3 37



**Year of Expiration – 2002**

<b>Drug ON-OFF Patent</b>	<b>Generic Name</b>	<b>Patent Holder Marketer</b>	<b>Patent Expiry</b>	<b>Exclusivity Expiry</b>	<b>Patent &amp; Exclusivity</b>	<b>Earliest Generic</b>	<b>1998 1999<sup>1</sup></b>
Trade	Generic	NAME	<b>Patent #</b>	DATE	CODES	DATE	USD\$ (Mil)
Prandin	Repaglinide	Novo Nordisk	<b>10/06/06 5-216-167</b>	<b>12/22/02</b>	- NCE	<b>12/22/02</b>	Class 3 31
Rilutek	Riluzole	Rhone-Poulenc Rorer	- <b>P</b>	<b>12/23/02</b>	- NCE,ODE	<b>12/23/02</b>	Class 3 24
Optiray 350	loversol	Mallinkrodt	<b>12/30/02 4-396-598</b>	-	- -	<b>12/30/02</b>	Class 4 59

**Note: Some Brand leader drugs products have been omitted due to non-availability of sales data which will appear in the 2000/2001 report**

NA = Not Applicable  
NCE = New Chemical Entity  
NDF = New Dosage Form

NC = Not confirmed in 1997  
NS = New Substance  
NC = New Combination

ODE = Orphan Drug Exclusivity  
NP = New Product  
NE = New Salt or Ester

**USD \$**

Class 1 -<**10**m ; Class 2 -<**25**m ; Class 3 -<**50**m ; Class 4 -<**75**m ; Class 5 -<**100**m Class 6 ->**100**m

**Year of Expiration - 2003****Under \$100 million USD**

<b>Drug ON-OFF Patent</b>	<b>Generic Name</b>	<b>Patent Holder Marketer</b>	<b>Patent Expiry</b>	<b>Exclusivity Expiry</b>	<b>Patent &amp; Exclusivity</b>	<b>Earliest Generic</b>	<b>1998 1999<sup>1</sup></b>
Trade	Generic	NAME	Patent #	DATE	CODES	DATE	USD\$ (Mil)
Fludara	Fludarabine Phosphate	Berlex	02/24/03 4-357-324	04/18/98	- ODE	02/24/03	Class 3 46
Brevibloc	Esmolol HCl	BOC Group/ Ohmeda	06/03/03 4-593-119	-	- -	06/03/03	Class 2 25
Decabid	Indecainide	Lilly	06/05/03 4-452-745	-	- -	06/05/03	-
Dynacirc	Isradipine	Novartis	08/21/03 4-466-972	-	U-3 -	08/21/03	Class 3 44
Dynacirc CR	Isradipine	Novartis	08/21/03 4-466-972	-	- -	08/21/03	Class 2 13
Renormax	Spirapril HCl	Schering	09/11/03 4-470-972	12/29/99	U-3 NCE	09/11/03	-
Sildimac	Silver Sulfadiazinc	NA	01/07/03 4-563-184	-	- -	01/07/03	-
Serax	Oxazepam	AHP Wyeth - Ayerst	11/04/03 4-620-974	-	- -	11/04/03	Class 1 7
Blenaxane	Bleomysin sulfate	Bristol-Myers Squibb	- P	02/20/03	- OdE	02/20/03	Class 2 24
Xeloda	Capecitabine	Roche	- P	04/30/03	- NCE	04/30/03	Class 2 24
Advil Cold and Sinus	Ibuprofen	AHP/Wyeth -Ayerst	05/12/ 03 4-552-899 *PED	-	- -	05/12/03	Class 3 26
Diprolene	Betamethasone Dipropionate	Schering-Plough	05/13/03 4-489-070	-	- -	05/13/03	Class 3 34
Diprolene AF	Betamethasone Dipropionate	Schering-Plough	12/09/03 4-489-071	-	- -	12/09/03	Class 3 45
Ocuflox	Ofloxacin	Allergan	05/10/00 4-382-892	05/22/03	- ODE	05/22/03	Class 3 34
Celexa	Citalopram Hydrobromide	Forest Lab.	- P	07/17/03	- NCE	07/17/03	Class 3 45
Renova	Tretinoin	Johnson & Johnson	07/29/03 4-603-146	12/28/98	U-131 NDE	07/29/03	Class 3 26
Lotensin HCT	Benazepril	Novartis	08/12/03 4-410-521	-	- -	08/12/03	Class 3 54
Serostim	Somatropin , biosynthetic	Ares Serono	- P	08/23/03	- ODE	08/23/03	Class 3 37

## Year of Expiration – 2003

<b>Drug ON-OFF Patent</b>	<b>Generic Name</b>	<b>Patent Holder Marketer</b>	<b>Patent Expiry</b>	<b>Exclusivity Expiry</b>	<b>Patent &amp; Exclusivity</b>	<b>Earliest Generic</b>	<b>1998 1999<sup>1</sup></b>
Trade	Generic	NAME	<b>Patent #</b>	DATE	CODES	DATE	USD\$ (Mil)
Topamax	Topiramate	R.W. Johnson	<b>09/26/03 4-513-006</b>	<b>12/24/01</b>	- NCE	<b>09/26/03</b>	Class 4 64
Abelcet	Amphotericin B	Liposome	- P	<b>10/18/03</b>	- ODE	<b>10/18/03</b>	Class 3 47
Cutivate	Fluticasone propionate	Glaxo- Wellcome	<b>11/14/03 4-335-121</b>	-	- -	<b>11/14/03</b>	Class 2 16
Copaxone	Glatiramer acetate	Teva Marion Partners	- P	<b>12/20/03</b>	- NCE,ODE	<b>12/20/03</b>	Class 3 53

**Note: Some Brand leader drugs products have been omitted due to non-availability of sales data which will appear in the 2000/2001 report**

NA = Not Applicable	NC = Not confirmed in 1998	ODE = Orphan Drug Exclusivity
NCE = New Chemical Entity	NS = New Substance	NP = New Product
NDF = New Dosage Form	NC = New Combination	NE = New Salt or Ester

### USD \$

Class 1 -<10m ; Class 2 -<25m ; Class 3 -<50m ; Class 4 -<75m ; Class 5 -<100m Class 6 ->100m

## Year of Expiration - 2004

### Under \$100 million USD

Drug on Patent	Generic Name	Patent Holder Marketer	Patent Expiry	Exclusivity Expiry	Patent & Exclusivity	Earliest Generic	1998 1999 <sup>1</sup>
Protropin	Somatrem	Genentech	04/14/04 4-658-021	-	- -	04/14/04	Class 1 4
Ciloxan	Ciprofloxacin HCl	Alcon	06/02/04 4-670-444	03/30/01	U-223 NDF	06/02/04	Class 3 36
Adenocard	Adenosine	Fujisawa	06/16/04 4-673-563	-	U-38 -	06/16/04	Class 2 22
Ergamisol	Levamisole	Johnson & Johnson	06/19/04 4-584-305	-	U-42 -	06/19/04	Class 1 6
Dipentum	Olsalazine Sodium	Pharmacia Adria	08/04/04 4-559-330	-	U-58 -	08/04/04	Class 2 14
Tambocor	Flecainide acetate	3M Pharmaceuticals	02/10/04 4-642-384	-	- -	02/10/04	Class 3 45
Maxair	Pirbuterol acetate	3M Pharmaceuticals	05/12/04 4-664-107	-	- -	05/12/04	Class 2 21
Ambisome	Amphotericin B	Fujisawa	- P	08/11/04	- ODE	08/11/04	Class 2 20
Aldara	Imiquimod	3M Pharmaceuticals	08/25/04 4-689-338	02/27/02	U-172 NCE	08/25/04	Class 3 29
Lariam	Mefloquine HCl	Roche	10/01/04 4-579-855	-	- -	10/01/04	Class 3 28
Romazicon	Flumazenil	Roche	10/10/04 4-316-839	-	- -	10/10/04	Class 3 35
Genotropin	Somatropin biosynthetic	Pharmacia Upjohn	- P	10/31/04	- ODE	10/31/04	Class 4 27
Livostin	Levocabastine HCl	Novartis	12/02/04 4-369-184	11/10/98	- NCE	12/02/04	Class 2 25
Ultravate	Halobetasol Propionate	Bristol-Myers Squibb	12/17/04 4-619-921	-	- -	12/17/04	Class 3 41
Vicoprofen	Hydrocodone Bitrtrate	Knoll	12/18/04 4-587-252	09/23/00	U-55 NC	12/18/04	Class 3 46
TOBI	Tobramycin	Pathogenesis	- *	12/22/04	- ODE	12/22/04	Class 3 45

**Note: Some Brand leader drugs products have been omitted due to non-availability of sales data which will appear in the 2000/2001 report**

#### USD \$

Class 1 -<10m ; Class 2 -<25m ; Class 3 -<50m ; Class 4 -<75m ; Class 5 -<100m Class 6 ->100m

NA = Not Applicable  
NCE = New Chemical Entity  
NDF = New Dosage Form

NC = Not confirmed in 1998  
NS = New Substance  
NC = New Combination

ODE = Orphan Drug Exclusivity  
NP = New Product  
NE = New Salt or Ester

**Year of Expiration - 2005**  
**Under \$100 million USD**

<b>Drug ON-OFF Patent</b>	<b>Generic Name</b>	<b>Patent Holder Marketer</b>	<b>Patent Expiry</b>	<b>Exclusivity Expiry</b>	<b>Patent &amp; Exclusivity</b>	<b>Earliest Generic</b>	<b>1998 1999<sup>1</sup></b>
Trade	Generic	NAME	Patent #	DATE	CODES	DATE	USD\$ (Mil)
Testoderm	Testosterone	Alza Corp.	02/16/05 4-867-982	-	- -	02/16/05	Class 1 3
Nuromax	Doxacurium Chloride	Glaxo Wellcome	03/06/05 4-701-460	12/08/97	- I-121	03/06/05	Class 1 1
Ganite	Gallium Nitrate	Sloan Keterring	01/17/05 4-529-593	01/17/98	U-49 ODE	01/17/05	Class 1 1
Survanta	Beractant	Abbott	07/01/05 4-397-839	07/01/98	- ODE	07/01/05	Class 4 67
Fragmin	Dalteparin Sodium	Pharmacia Upjohn	01/04/05 4-303-651	12/22/99	- NCE	01/04/05	Class 2 14
Salagen	Pilocarpine HCl	MGI Pharma	- -	02/11/05	- ODE	02/11/05	Class 2 13
Ultravist	Iopromide	Berlex	03/06/05 4-364-921	05/10/00	U-13 NCE	03/06/05	Class 2 17
Amaryl	Glimepiride	Hoechst-Marion Roussel	04/06/05 4-379-785	11/30/00	U-118 NCE	04/06/05	Class 4 64
Fentanyl	Fentanyl Citrate	AHP Wyeth Ayerst	05/01/05 4-671-953	-	U-87 -	05/01/05	Class 1 20
Cytovene	Ganciclovir Sodium	Roche	06/24/05 4-642-346	10/27/98	- I-140	06/24/05	Class 4 80
Lupron Depot Ped	Leuprolide acetate	TAP Pharm.	07/03/05 4-677-191	04/16/00	- ODE	07/03/05	Class 3 28
Lexxel	Enalapril maleate	Merck & Co	10/07/05 4-703-038	12/27/99	- NC	10/07/05	Class 1 11
Cholybar	Cholestyramine	Warner - Wellcome	10/18/05 4-778-676	-	- -	10/18/05	NA

**USD \$**

Class 1 -<10m ; Class 2 -<25m ; Class 3 -<50m ; Class 4 -<75m ; Class 5 -<100m Class 6 ->100m

NA = Not Applicable  
 NCE = New Chemical Entity  
 NDF = New Dosage Form

NC = Not confirmed in 1998  
 NS = New Substance  
 NC = New Combination

ODE = Orphan Drug Exclusivity  
 NP = New Product  
 NE = New Salt or Ester

**Year of Expiration - 2006****Under \$100 million USD**

<b>Drug ON-OFF Patent</b>	<b>Generic Name</b>	<b>Patent Holder Marketer</b>	<b>Patent Expiry</b>	<b>Exclusivity Expiry</b>	<b>Patent &amp; Exclusivity</b>	<b>Earliest Generic</b>	<b>1998 1999<sup>1</sup></b>
Trade	Generic	NAME	Patent #	DATE	CODES	DATE	USD\$ (Mil)
Mivacron	Mivacurium Chloride	Glaxo Wellcome	01/22/06 4-761-418	01/22/97	- NCE	01/22/06	Class 2 20
Omniflox	Ternafloxacin HCl	Abbott	01/30/06 4-730-000	01/30/97	U-36 NCE	01/30/06	NA
Aceon	Perindopril Erbumine	Adir	08/21/06 4-508-729	12/30/98	- NCE	08/21/06	NA
Timoptic-XE	Timolol Maleate	Merck & Co.	08/29/06 4-861-760	-	- -	08/29/06	Class 5 85
Videx	Didanosine	Bristol Myers-Squibb	08/29/06 4-861-759	-	- -	08/29/06	Class 4 63
Tilade	Nedocromil Sodium	Schering-Plough	10/02/06 4-474-787	10/01/00	- NDF	10/02/06	Class 2 20
Mivacron	Mivacurium Chloride	Glaxo Wellcome	//06 4--	//06	- -	//06	Class
Metrogel	Metronidazole	Galderma	06/06/06 4-837-378	-	- -	06/06/06	Class 3 47
Flomax	Tamulosin HCl	Boehringer Ingelheim	09/19/06 4-868-216	04/15/02	U-181 NCE	09/19/06	Class 4 64
Phoslo	Calcium Acetate	Braintree	09/26/06 4-870-105	12/10/97	- ODE	09/26/06	Class 2 17
Prohance	Gadoteridol	Bracco	12/05/06 4-885-363	11/16/06	- NCE	12/05/06	Class 3 27
Mirapex	Pramipexole dihydrochloride hydrate	Pharmacia Upjohn	12/12/06 4-866-812	07/01/02	- NCE	12/12/06	Class 3 47

**Note: Some Brand leader drugs products have been omitted due to non-availability of sales data which will appear in the 1999/2001 report.**

**USD \$**

Class 1 -<10m ; Class 2 -<25m ; Class 3 -<50m ; Class 4 -<75m ; Class 5 -<100m Class 6 ->100m

NA = Not Applicable  
NCE = New Chemical Entity  
NDF = New Dosage Form

NC = Not confirmed in 1998  
NS = New Substance  
NC = New Combination

ODE = Orphan Drug Exclusivity  
NP = New Product  
NE = New Salt or Ester

**Year of Expiration - 2007****Under \$100 million USD**

<b>Drug ON-OFF Patent</b>	<b>Generic Name</b>	<b>Patent Holder Marketer</b>	<b>Patent Expiry</b>	<b>Exclusivity Expiry</b>	<b>Patent &amp; Exclusivity</b>	<b>Earliest Generic</b>	<b>1998 1999<sup>1</sup></b>
Trade	Generic	NAME	Patent #	DATE	CODES	DATE	USD\$ (Mil)
Dovonex	Calcipotriene	Bristol - Myers Squibb	<b>12/29/07</b> <b>4-866-048</b>	<b>03/03/00</b>	U-88 NCE,NDF	<b>12/29/07</b>	Class 5 91
Betaseron	Interferon beta 1	Berlex	<b>07/13/07</b> <b>4-588-585</b>	-	- -	<b>07/13/07</b>	Class 2 17
Nasocort	Triamcinolone acetonide	Rhone Poulenc Rorer	<b>01/23/07</b> <b>4-767-612</b>	<b>05/20/99</b>	U-85 I-162	<b>01/23/07</b>	Class 4 74
Suprane	Desflurane	BOC Group/ Ohmeda	<b>02/02/07</b> <b>4-762-856</b>	<b>09/18/97</b>	U-67 NCE	<b>02/02/07</b>	Class 4 80
Precose	Acarbose	Bayer	<b>02/27/07</b> <b>4-904-769</b>	<b>09/06/00</b>	- NCE	<b>02/27/07</b>	Class 3 35
Maxipime	Cefepime	Bristol Meyers Squibb	<b>03/04/07</b> <b>4-406-899</b>	-	- -	<b>03/04/07</b>	Class 2 18
Pulmicort	Budesonide	Astra Zeneca	<b>03/13/07</b> <b>4-907-583</b>	<b>02/14/99</b>	- NCE	<b>03/13/07</b>	Class 3 45
Omniscan inj.	Gadodiamide	Sanofi Winthrop	<b>05/04/07</b> <b>4-687-659</b>	<b>01/08/98</b>	U-76 NCE	<b>05/04/07</b>	Class 3 45
Naserel	Flunisolide	Roche	<b>06/12/07</b> <b>4-933-168</b>	-	- -	<b>06/12/07</b>	Class 2 16
Tarka	Trandolapril	Knoll	<b>06/12/07</b> <b>4-933-361</b>	<b>04/26/01</b>	- NCE	<b>06/12/07</b>	Class 2 15
Nasalide	Flunisolide	Roche	<b>06/12/07</b> <b>4-933-168</b>	-	- -	<b>06/12/07</b>	Class 2 13
Cerebyx	Fosphenytoin Sodium	Warner Lambert	<b>08/05/07</b> <b>4-925-860</b>	<b>08/05/03</b>	- ODE	<b>08/05/07</b>	Class 3 34
Posicor	Miberfradiil dihydrochlori de	Roche	<b>11/10/07</b> <b>4-808-605</b>	<b>06/20/02</b>	- NCE	<b>11/10/07</b>	Class 2 23
Pentasa	Mesalamine	Hoechst Marion Roussel	<b>12/25/07</b> <b>4-980-173</b>	-	U-78 -	<b>12/25/07</b>	Class 3 38

**Note: Some Brand leader drugs products have been omitted due to non-availability of sales data which will appear in the 2000/2001 report**

**USD \$**

Class 1 -<**10**m ; Class 2 -<**25**m ; Class 3 -<**50**m ; Class 4 -<**75**m ; Class 5 -<**100**m Class 6 ->**100**m

NA = Not Applicable  
NCE = New Chemical Entity  
NDF = New Dosage Form

NC = Not confirmed in 1998  
NS = New Substance  
NC = New Combination

ODE = Orphan Drug Exclusivity  
NP = New Product  
NE = New Salt or Ester

**Year of Expiration - 2008****Under \$100 million USD**

<b>Drug ON-OFF Patent</b>	<b>Generic Name</b>	<b>Patent Holder Marketer</b>	<b>Patent Expiry</b>	<b>Exclusivity Expiry</b>	<b>Patent &amp; Exclusivity</b>	<b>Earliest Generic</b>	<b>1998 1999<sup>1</sup></b>
Trade	Generic	NAME	Patent #	DATE	CODES	DATE	USD\$ (Mil)
Ifex	Ifosfomide	Bristol Myers - Squibb	<b>03/03/08</b> <b>4-882-452</b>	-	- -	<b>03/03/08</b>	Class 4 80
Neurolite	Technetium	DuPont	<b>11/23/08</b> <b>5-279-811</b>	<b>11/23/99</b>	U-101 NCE	<b>11/23/08</b>	NA
Semprex-D	Acrivastine	Glaxo- Wellcome	<b>03/26/08</b> <b>4-650-807</b>	<b>03/25/97</b>	U-93 NC	<b>03/26/08</b>	Class 2 11
Actinex Cream	Masoprocol	Reed & Carnick	<b>04/17/08</b> <b>4-695-590</b>	<b>09/04/07</b>	- NCE	<b>04/17/08</b>	
Hivid	Zalcitabine	Roche	<b>07/02/08</b> <b>5-028-595</b>	<b>06/19/97</b>	U-65 NCE	<b>07/02/08</b>	Class 2 14
Trusopt	Dorzolamide HCl	Merck & Co	<b>04/28/08</b> <b>4-797-413</b>	<b>12/09/99</b>	- NCE	<b>04/28/08</b>	Class 5 100+
Requip	Ropinirole HCl	Smith Kline Beecham	<b>05/19/08</b> <b>4-854-860</b>	<b>09/19/02</b>	U-212 NCE	<b>05/19/08</b>	Class 2 21
Restoril	Temazepam Hydrochloride	Novartis	<b>07/09/08</b> <b>5-326-758</b>	-	U-70 -	<b>07/09/08</b>	Class 2 18
Amerge	Naratriptan Hcl	Glaxo- Wellcome	<b>08/12/08</b> <b>4-997-841</b>	<b>02/10/03</b>	U-232 NCE	<b>08/12/08</b>	Class 3 36
Alkeran	Melphalan	Glaxo- Wellcome	<b>11/18/08</b> <b>4-997-651</b>	<b>11/18/99</b>	- ODE	<b>11/18/08</b>	Class 2 15

**Note: Some Brand leader drugs products have been omitted due to non-availability of sales data which will appear in the 2000/2001 report**

**USD \$**

Class 1 -<**10m** ; Class 2 -<**25m** ; Class 3 -<**50m** ; Class 4 -<**75m** ; Class 5 -<**100m** Class 6 ->**100m**

NA = Not Applicable

NCE = New Chemical Entity

NDF = New Dosage Form

NC = Not confirmed in 1998

NS = New Substance

NC = New Combination

ODE = Orphan Drug Exclusivity

NP = New Product

NE = New Salt or Ester



**Year of Expiration - 2009****Under \$100 million USD**

<b>Drug ON-OFF Patent</b>	<b>Generic Name</b>	<b>Patent Holder Marketer</b>	<b>Patent Expiry</b>	<b>Exclusivity Expiry</b>	<b>Patent &amp; Exclusivity</b>	<b>Earliest Generic</b>	<b>1998 1999<sup>1</sup></b>
Trade	Generic	NAME	Patent #	DATE	CODES	DATE	USD\$ (Mil)
Permax	Pergolide Mesylate	Athena Neuroscience	<b>10/19/09</b> <b>5-114-948</b>	-	-	<b>10/19/09</b>	Class 3 40
Ultiva	Remifen-tanil HCl	Glaxo - Wellcome	<b>02/15/09</b> <b>5-019-583</b>	<b>07/12/01</b>	- NCE	<b>02/15/09</b>	Class 1 5
Baycol	Cerivastin Sodium	Bayer	<b>01/17/09</b> <b>5-006-530</b>	<b>06/26/02</b>	- NCE	<b>01/17/09</b>	Class 3 29
Tricor (micronised)	Fenofibrate	Fournier Research	<b>01/19/09</b> <b>4-895-726</b>	-	- -	<b>01/19/09</b>	Class 2 15
Mepron	Atovaquone	Glaxo - Wellcome	<b>08/15/09</b> <b>4-981-874</b>	<b>01/05/06</b>	- ODE	<b>08/15/09</b>	Class 2 23
Astelin	Azelastine HCl	Carter Wallace	<b>11/17/09</b> <b>5-164-194</b>	<b>11/01/01</b>	U-207 NCE	<b>11/17/09</b>	Class 3 38
Migranal	Dihydro ergotamine Mesylate	Novartis	<b>12/08/09</b> <b>5-169-849</b>	<b>12/08/00</b>	- NDF	<b>12/08/09</b>	Class 2 18
Arimidex	Anastrozole	Astra Zeneca	<b>12/27/09</b> <b>4-935-437</b>	<b>12/27/00</b>	- NCE	<b>12/27/09</b>	Class 3 45
Andro-derm	Testosterone	Smith Kline Beecham	<b>10/06/09</b> <b>5-152-997</b>	-	- -	<b>10/06/09</b>	Class 2 21

**Note: Some Brand leader drugs products have been omitted due to non-availability of sales data which will appear in the 2000/2001 report.**

**USD \$**

Class 1 -<10m ; Class 2 -<25m ; Class 3 -<50m ; Class 4 -<75m ; Class 5 -<100m Class 6 ->100m

NA = Not Applicable

NCE = New Chemical Entity

NDF = New Dosage Form

NC = Not confirmed in 1998

NS = New Substance

NC = New Combination

ODE = Orphan Drug Exclusivity

NP = New Product

NE = New Salt or Ester

**Year of Expiration - 2010****Under \$100 million USD**

<b>Drug ON-OFF Patent</b>	<b>Generic Name</b>	<b>Patent Holder Marketer</b>	<b>Patent Expiry</b>	<b>Exclusivity Expiry</b>	<b>Patent &amp; Exclusivity</b>	<b>Earliest Generic</b>	<b>1998 1999<sup>1</sup></b>
Trade	Generic	NAME	Patent #	DATE	CODES	DATE	USD\$ (Mil)
Kadian	Morphine Sulphate	Faulding	04/13/10 5-202-128	07/03/99	- NDF	04/13/10	Class 1 4
Feridex	Ferumoxides	Advanced Magnetics	09/28/10 5-248-492	08/30/01	- NCE	09/28/10	Class 1 1
Iodipine	Apraclonidine Hydrochloride	Alcon	05/18/10 4-517-199	-	U-120,U-15 -	05/18/10	Class 2 19
Hycamtin	Topotecan HCl	Smith Kline Beecham	05/28/10 5-004-758	05/28/01	- NCE	05/28/10	Class 4 78
Climara	Estradiol	Berlex	06/29/10 5-223-261	03/05/02	- I-254	06/29/10	Class 4 72
Invirase	Saquinavir Mesylate	Roche	11/19/10 5-196-438	12/06/00	- NCE	11/19/10	Class 4 67
Patanol	Olopatadine HCl	Alcon	12/18/10 5-116-863	12/18/01	- NCE	12/18/10	Class 4 73

**Note: Some Brand leader drugs products have been omitted due to non-availability of sales data which will appear in the 2000/2001 report.**

**USD \$**

Class 1 -<10m ; Class 2 -<25m ; Class 3 -<50m ; Class 4 -<75m ; Class 5 -<100m Class 6 ->100m

NA = Not Applicable

NCE = New Chemical Entity

NDF = New Dosage Form

NC = Not confirmed in 1998

NS = New Substance

NC = New Combination

ODE = Orphan Drug Exclusivity

NP = New Product

NE = New Salt or Ester

## Year of Expiration - 2011

### Under \$100 million USD

Drug ON-OFF Patent	Generic Name	Patent Holder Marketer	Patent Expiry	Exclusivity Expiry	Patent & Exclusivity	Earliest Generic	1998 1999 <sup>1</sup>
Trade	Generic	NAME	Patent #	DATE	CODES	DATE	USD\$ (Mil)
Synarel	Naferlin Acetate	Roche	06/11/11 4-234-571	-	-	06/11/11	Class 1 10
Visipaque 270	Iodixanol	Nycomed	09/20/11 5-349-085	03/22/01	- NCE	09/20/11	Class 3 39
Avapro	Ibesartan	Sanofi/BMY	03/20/11 5-270-317	09/30/02	- NCE	03/20/11	Class 4 72
Follistim	Follitropin Alfa/beta	Organon	03/20/11	09/29/00	- NP	03/20/11	Class 4 56
Astelin	Azelastine Hcl	Wallace	10/16/11 5-164-194	-	U-207 -	10/16/11	Class 3 37
Viramune	Nevirapine	Boehringer Ingleheim	11/22/11 5-366-972	06/21/01	U-167 NCE	11/22/11	Class 5

**Note: Some Brand leader drugs products have been omitted due to non-availability of sales data which will appear in the 2000/2001 report.**

#### USD \$

Class 1 -<10m ; Class 2 -<25m ; Class 3 -<50m ; Class 4 -<75m ; Class 5 -<100m Class 6 ->100m

NA = Not Applicable

NCE = New Chemical Entity

NDF = New Dosage Form

NC = Not confirmed in 1998

NS = New Substance

NC = New Combination

ODE = Orphan Drug Exclusivity

NP = New Product

NE = New Salt or Ester

**Year of Expiration - 2012****Under \$100 million USD**

<b>Drug ON-OFF Patent</b>	<b>Generic Name</b>	<b>Patent Holder Marketer</b>	<b>Patent Expiry</b>	<b>Exclusivity Expiry</b>	<b>Patent &amp; Exclusivity</b>	<b>Earliest Generic</b>	<b>1998 1999<sup>1</sup></b>
Trade	Generic	NAME	Patent #	DATE	CODES	DATE	USD\$ (Mil)
Photofrin	Porfimer Sodium	QLT Photo Therapeutics	08/01/12 5-438-071	12/27/00	U-128 NCE	08/01/12	Class 1 4
Imodium Advanced	Loperamide HCl	Johnson & Johnson	05/21/12 5-716-641	06/26/00	- NC	05/21/12	Class 2 15
Gabitril	Tiagabine HCl	Abbott	03/24/12 -	09/30/02	- NCE	03/24/12	Class 2 14
Motrin	Ibuprofen	Johnson & Johnson	06/20/12 5-374-659*PED	-	- -	06/20/12	Class 2 22
Tasmar	Tolcapone	Roche	12/19/12 5-476-875	01/29/03	- NCE	12/19/12	Class 3 31
Fortovase	Saquinavir	Roche	11/19/12 5-196-438	12/06/00	- NCE	11/19/12	Class 4 78
Diovan HCT	Valsartan-hydrochlor-thiazide	Novartis	03/21/12 5-399-578	12/23/01	U-3 NCE	03/21/12	Class 2 20
Nimbex	Cisatracurium Besylate	Glaxo Wellcome	09/26/12 5-453-510	12/15/98	U-127 NE	09/26/12	Class 3 36

**Note: Some Brand leader drugs products have been omitted due to non-availability of sales data which will appear in the 2000/2001 report.**

**USD \$**

Class 1 -<10m ; Class 2 -<25m ; Class 3 -<50m ; Class 4 -<75m ; Class 5 -<100m Class 6 ->100m

NA = Not Applicable

NCE = New Chemical Entity

NDF = New Dosage Form

NC = Not confirmed in 1998

NS = New Substance

NC = New Combination

ODE = Orphan Drug Exclusivity

NP = New Product

NE = New Salt or Ester

**Year of Expiration - 2013****Under \$100 million USD**

<b>Drug ON-OFF Patent</b>	<b>Generic Name</b>	<b>Patent Holder Marketer</b>	<b>Patent Expiry</b>	<b>Exclusivity Expiry</b>	<b>Patent &amp; Exclusivity</b>	<b>Earliest Generic</b>	<b>1998 1999<sup>1</sup></b>
Trade	Generic	NAME	Patent #	DATE	CODES	DATE	USD\$ (Mil)
Cerezyme	Imiglucerase	Genzyme	<b>08/28/13</b> <b>5-549-892</b>	<b>05/23/01</b>	U-252 NCE,ODE	<b>08/28/13</b>	Class 2 16
Humalog	Insulin Lispro	Eli Lilly	<b>05/07/13</b> <b>5-514-646</b>	<b>06/14/01</b>	U-111 NCE	<b>05/07/13</b>	Class 4 63
Raxar	Grepafloxacin HCl	Glaxo- Wellcome	<b>10/08/13</b> <b>5-563-183</b>	<b>11/06/02</b>	- NCE	<b>10/08/13</b>	Class 2 15
Crinone	Progesterone	AHP/Wyeth- Ayerst	<b>09/15/13</b> <b>5-543-150</b>	<b>07/13/00</b>	- NP	<b>09/15/13</b>	Class 2 19
Propecia	Finasteride	Merck & Co	<b>10/15/13</b> <b>5-547-957</b>	<b>12/19/00</b>	U-236 NP	<b>10/15/13</b>	Class 3 36

**Note: Some Brand leader drugs products have been omitted due to non-availability of sales data which will appear in the 2000/2001 report.**

**USD \$**

Class 1 -<**10m** ; Class 2 -<**25m** ; Class 3 -<**50m** ; Class 4 -<**75m** ; Class 5 -<**100m** Class 6 ->**100m**

NA = Not Applicable

NCE = New Chemical Entity

NDF = New Dosage Form

NC = Not confirmed in 1998

NS = New Substance

NC = New Combination

ODE = Orphan Drug Exclusivity

NP = New Product

NE = New Salt or Ester

# Drugs Off-Patent Reports

ISSN 0793694X

Electronic  Reports on Disk  
 Reports on Web   
 e- Reports

Year of Expiration - 2014 / 2015 / 2016 / 2017

<b>Drug ON-OFF Patent</b>	<b>Generic Name</b>	<b>Patent Holder Marketer</b>	<b>Patent Expiry</b>	<b>Exclusivity Expiry</b>	<b>Patent &amp; Exclusivity</b>	<b>Earliest Generic</b>	<b>1998 1999<sup>1</sup></b>
Trade	Generic	NAME	<b>Patent #</b>	DATE	CODES	DATE	USD\$ (Mil)
Sustiva	Efavirenz	DuPont Pharm.	<b>09/02/14</b> <b>5-663-169</b>	<b>09/17/03</b>	- NCE	<b>09/02/14</b>	Class 2 18
Mavik	Trandolapril	BASF	<b>04/28/15</b> <b>5-744-496</b>	<b>04/26/01</b>	- NCE	<b>04/28/15</b>	Class 2 18
Gonal-F	Follitropin Alpha/beta	Serona Laboratories	<b>06/16/15</b> <b>5-767-251</b>	<b>06/16/15</b>	- -	<b>06/16/15</b>	Class 4 85
Adenoscan	Adenosine	Jujisawa	<b>03/24/15</b> <b>5-731-296</b>	<b>05/18/98</b>	U-221 I-126	<b>03/24/15</b>	Class 3 55
Proventil-HFA	Albuterol sulfate	Schering-Plough	<b>06/16/15</b> <b>5-766-573</b>	<b>09/23/01</b>	- I-235	<b>06/16/15</b>	Class 4 69
Proventil-HFA	Albuterol sulfate	Schering-Plough	<b>06/16/15</b> <b>5-766-573</b>	<b>09/23/01</b>	- I-235	<b>06/16/15</b>	Class 4 69
Aggrastat	Tibofiban HCl	Merck & Co.	<b>10/23/16</b> <b>5-733-919</b>	<b>05/14/03</b>	- NCE	<b>10/23/16</b>	Class 2 18

**USD \$**

Class 1 -<10m ; Class 2 -<25m ; Class 3 -<50m ; Class 4 -<75m ; Class 5 -<100m Class 6 ->100m

This Drugs OFF Patent Series will be continued annually:-

**2000**  
**2001**  
**2003**  
 to the year  
**2017**